Polychromatic-Light Irradiation Kinetics of Dacarbazine and Nifedipine. Application as New Reliable UVA-drug-actinometers.

Mounir Maafi (✉ mmaafi@dmu.ac.uk)

De Montfort University

Mohammed Ahmed Al-Qarni

Taif University

Research Article

Keywords: drugs photostability, photodegradation, polychromatic light, photokinetics, η -order kinetics, actinometry.

Posted Date: September 23rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-892469/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Polychromatic-light irradiation kinetics of**
2 **Dacarbazine and Nifedipine.**

3 **Application as new reliable UVA-drug-actinometers.**

4
5
6 Mounir Maafi ^{a,*}, Mohammed Ahmed Al-Qarni ^b

7
8
9 ^a *Leicester School of Pharmacy, De Montfort University, The Gateway, Leicester LE1*
10 ^{9BH, UK.}

11 ^bDepartment of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O.
12 Box 11099, Taif 21944, Saudi Arabia.

13
14
15
16
17 * Corresponding author

18 Tel.: +44 116 257 7704

19 Fax: +44 116 257 7287

20 E-mail address: mmaafi@dmu.ac.uk

Abstract Graphics

Abstract

The photokinetic behaviour of materials driven by polychromatic light is an area that has not received a lot of attention in the literature. Most often, such photokinetic data is treated by thermal kinetic models (i.e., the classical 0th-, 1st- or 2nd-order equations). Such models were not analytically derived from the rate-laws of the photodegradation reactions. Polychromatic light kinetic modelling is hence of importance, as a means to providing adequate toolkits and metrics. This paper aims at proposing two reliable drug-actinometers useful for polychromatic UVA range. The general actinometric methodology offered here is also useful for any drugs/materials obeying a primary photoprocess where both reactant and photoproduct absorb the incident light, of the $AB(1\Phi)_{\varepsilon_B \neq 0}$ type. The present method has been consolidated by the η -order kinetics, a mathematical model analytically derived from the photosystem's rate-law. This represents the first ever equation in the literature, to model polychromatic light of this reactive system. This framework further demonstrated the lamp-specificity of actinometers. Overall, Dacarbazine and Nifedipine photodegradations obeyed η -order kinetics, and stand as effective actinometers that can be recommended for the ICH Q1b photostability testing.

Keywords: drugs photostability; photodegradation; polychromatic light; photokinetics; η -order kinetics; actinometry.

1. Introduction

Photostability of drugs is an important part of drugs' stability studies [1-3]. The International Council on Harmonisation Q1b report [4] gives the procedures adopted for stress testing and photostability of new drug substances and products. It is therein recommended that photostability studies are conducted on the API both in its pure chemical form, and in its final pharmaceutical formulation. These considerations significantly contribute to the quality and safety of pharmaceuticals over their lifetime from production to patient, including technical production, storage, manipulation, administration and within the patient body [1-5]. Such photostability studies are also mandatory considering both the large number of photosensitive drugs, and the effects of light on their potency, efficacy, and adverse biological effects [1-3, 6-10]. Drugs' photodegradation also raised serious concerns about the impact their presence or the presence of their photoproducts may have in the environment [11-12].

Despite the extended documentation in the drug photodegradation field, there were only a few interesting discussions in relation to the procedures, the metrics and the overall quality of the existing photodegradation data [1-3,9-12]. For instance, the ICH Q1b report [4] does not specify how the kinetic data collected on drugs' photodegradation should be treated in order to measure the reactions' parameters. Also, the literature does not provide consensus on whether the data treatment varies with regard to the photomechanism undergone by the drug or the experimental conditions employed. In this regard, there is no indication whether the type of light (mono- or polychromatic) requires any variation in the photokinetic treatment procedures or mathematical formulae. Finally, there are no databases for photodegradation metrics of drugs.

The quantification of photodegradation basically relies on kinetic studies. In general, the most often used approach, is the classical methodology that was designed for (thermal) chemical kinetics. Within this remit, some studies have introduced some modifications on the treatment (e.g., using sometime numerical integration methods, or introducing power series in the rate-law [2-3]). One can observe that even when modifications are introduced, the end formulae turn out to correspond to the general mathematical formulation of the classical chemical kinetics used for thermal reactions (mostly zeroth- or first-order kinetic model equations). It is however important to underline here that, despite their ubiquity, these formulae do not derive from closed-form integration of the rate-laws describing drugs' photodegradation. Such a situation raises a legitimate question on whether photodegradation of drugs must obey the classical kinetic type of reaction orders and whether its data must be treated according to that methodology.

It has previously been shown [13] that the reaction kinetics of the primary photoprocess whose photoproduct is transparent to the monochromatic irradiation light, $AB(1\Phi)_{\varepsilon_B=0}$, obeys the Φ -order kinetics. Mathematically, the latter is defined by a logarithmic function that carries an exponential term in its argument. The Φ -order kinetics defines a new reaction behaviour that is different from the ones undergone by pure thermal reactions.

It was also acknowledged that when the photoproduct absorbs the excitation light, i.e. $AB(1\Phi)_{\varepsilon_B \neq 0}$ systems as Nifedipine and Dacarbazine [14-15], the solution of the rate-law is not possibly derived analytically. This meant that the true kinetic order of this reaction is, thus far, not accessible. However, a robust semi-empirical approach has facilitated a working expression of the Φ -order kinetics type [14-15] for the

integrated rate-law for the $AB(1\Phi)_{\varepsilon_B \neq 0}$ reaction subjected to monochromatic light. Some of the relevant results facilitated by this approach were (i) the devising of a rationale and methodology based on simple integrated rate-laws, (ii) the quantification of the photoprotection of drugs that is induced by absorption competitors, (iii) the proof of self-photostabilisation of drugs by the exclusively increase of the drug's initial concentration, (iv) the evidenced increase of the photoreaction rate with decreasing initial concentration of the reactant, and (v) the establishment of a simple actinometric procedure to convert drugs obeying $AB(1\Phi)_{\varepsilon_B \neq 0}$ photomechanism into efficient and reliable actinometers for monochromatic light.

Our work on monochromatic light irradiation, was also extended to photoreversible drugs such as Montelukast, Sunitinib and oxyresveratrol [16-19], and multi-consecutive photodegradation reactions such that of Riboflavin [20]. For these cases, semi-empirical methods allowed to derive algebraic formulae for the integrated rate-law equations according to Φ -order kinetics.

Such an effort could be seen as a contribution both to establish a reliable methodology for photodegradation studies, and to harmonise the area of quantifying drugs' photodegradation with specific and well-defined metrics.

Within this objective, there is still a gap in the knowledge that needs to be addressed. Notwithstanding the progress that has been achieved on modelling drugs' photodegradation under monochromatic light, there is very little known on the kinetic models for drugs exposed to polychromatic light. Most often, the kinetic behaviour under polychromatic light is assumed to obey the classical 0th- or 1st-orders of thermal reactions [1-3]. It is obvious that if the latter assumption does not apply to monochromatic light (i.e. the Φ -order kinetics template applies, as discussed above

[13-20]), it is reasonable to conjecture that it would, most likely, not apply when polychromatic light irradiation is considered.

Accordingly, in the present study, the investigation of polychromatic light induced kinetics is considered for the photoreaction $AB(1\Phi)_{\varepsilon_B \neq 0}$. The mathematical equations derived for this reaction are applied to the photodegradations of two drugs Dacarbazine and Nifedipine. In ethanol, the respective photodegradations of these drugs produce a single photoproduct [14-15]. Since, the photoproducts spectra overlap those of their respective reactants, their photoreactions belong to the $AB(1\Phi)_{\varepsilon_B \neq 0}$ family.

The anti-cancer drug Dacarbazine (DBZ), is used for the treatment of metastatic malignant melanoma, Hodgkin's disease and soft tissue sarcoma [21-27]. Nifedipine is an anti-hypertensive drug, a dihydropyridine that belongs to one of the three groups of calcium-channel blockers, i.e. benzothiazepines, dihydropyridines and phenylalkylamines [1-3,28-31].

Both drugs are known to undergo fast photodegradations. Their kinetics have usually been fitted to 0th- or 1st-order models, irrespective of whether the light employed was mono- or polychromatic [1-3,32-38]. In aqueous solutions, their photodegradations produce species responsible of phototoxic effects [1-3,36-37]. In this respect, developing robust kinetic strategies for both monochromatic and polychromatic light irradiations, will allow improving assessment and control of photodegradation.

2. Experimentals

2.1. Chemicals

Dacarbazine (DBZ), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, and Nifedipine (NIF), 3,5-dimethyl 2,6-dimethyl-(2nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and ethanol were purchased from Sigma-Aldrich.

2.2. Analytical solutions

Stock solutions of the drugs in ethanol, were prepared by weighing the solid. They were later used to prepare fresh diluted analytical solutions for experiments performed at various polychromatic irradiation conditions. Volumetric flasks and spectrophotometric cuvettes were protected from ambient light by aluminium foil wrapping.

The fresh solutions of the drugs had each the same concentration for actinometric experiments. They were exposed to the polychromatic light of a series of different intensities. The kinetic traces were collected and subsequently fitted with the appropriate equations.

2.3. Polychromatic irradiation

Four different lamps were used for the irradiation of the studied samples. Their light profiles (Fig.1) indicate emissions at different wavelength intervals, as indicated by the manufacturer, Fisher Scientific. These are Lamp #1, the 254-nm short-wavelength lamp model G6T/SW, Lamp #2, the 302-nm mid-wavelength range lamp model G6T5E, Lamp #3, the 365-nm long-wavelength lamp model F6T5, and Lamp #4, the

254/365-nm mixed-wavelength lamp model G6T5HC. These light sources had a 6W power.

For the purpose of the experiment, each of the above lamps was housed in designed handle, which is placed on the top of the irradiation cabinet (UPV C10-E6 mini UV viewing contrast contro). The inside of the cabinet is totally shielded from external light. This instrument was supplied by Fisher Scientific.

The studied solution held in the 1-cm cuvette reactor and continuously stirred, was placed inside the irradiation cabinet, maintained at given position under the lamp where the surface of the solution was perpendicular to the incident light beam.

Figure1. Light profile of the different light sources used in this study. The profiles were measured on an Avantes spectroradiometer.

The reduction of the light intensity, required for actinometric investigation, was achieved by placing one or more copper grid-mesh tiles above the reactor (as light intensity attenuating filters).

The sides of the reactor-cell (apart from the top section) were covered with aluminium foil, as to allow the lamp light to impinge on the sample from the top (collimated light irradiation). The volume of the sample irradiated in the reactor was 2 mL.

For each experiment, the radiant power profile of the selected lamp was measured using the spectroradiometer. Reaction media were removed from the cabinet at set irradiation time intervals, and analysed by either or both spectrophotometry and HPLC.

The lamps' profiles were obtained using an Avantes spectroradiometer model Avaspec/UL2048CL/EVO/50, using a UA-grating (200-1100 nm). The light beam reached the spectroradiometer through a slit-25 with a 400 μm optical fiber after correction by an in-line cosine corrector model FC/UVIR/1/BX and CC-UV/Vis. The collected profile intensities have the dimension $\text{mW}/\text{cm}^2/\text{nm}$ which has been converted to $\text{einstein}/\text{dm}^3/\text{s}$ as the unit required by photokinetics (Fig.1).

Measurements involving wavelength have been performed at 1 nm steps.

2.4. HPLC analyses

A Perkin Elmer HPLC instrument using a reversed-phase Waters symmetry (C18 150 mm x 3.9 mm, 5 μ) column, equipped with a Perkin Elmer Series 200 pump, UV/Vis detector, vacuum degasser and a Perkin Elmer type Chromatography Interface 600 series Link linked to a computer system, was used.

The mobile phases were obtained by automatically mixing two solvents. The mobile phase for NIF, was 55 % methanol and 45 % deionised water, that of DBZ, was 5 % acetonitrile and 95 % deionised water. A flow rate of 1 ml/min and an injection loop of 20 μ l were employed for both drugs. The UV-detector wavelength was set to 326 nm for NIF and 330 nm for DBZ.

The retention times of initial molecule and photoproduct were 6.86 and 5.28 min for NIF, and 5.09 min for DBZ. The respective calibration graphs of the mother compounds (Table 1) were built using peak areas (for HPLC), selected single wavelengths (spectrophotometry), or sum of absorbances (spectrophotometry).

All experiments were conducted, at least, in triplicates.

Table 1. Calibration features of the drugs.

Drug	Calibration graph	Linearity range $\times 10^{-5}$	Correlation
<i>Spectrophotometry (absorbance at a single wavelength)</i>			
DBZ	$4996 \times C + 0.0007$	1.50-10.74	0.999
NIF	$22545 \times C - 0.0628$	1.50-13.20	0.999
<i>HPLC (peak area)</i>			
DBZ	$4 \times 10^9 \times C - 18040$	1.72-27.50	0.999
NIF	$2 \times 10^9 \times C - 10810$	0.90-50.0	0.999
<i>Spectrophotometry (sum of absorbances)</i>			
DBZ	$1150804.8 \times C + 0.16$	1.50-10.74	0.999
DBZ-PP*	$345940 \times C + 0.041$		0.999
NIF	$1920969.95 \times C - 4.79$	1.50-13.20	0.999
NIF-PP*	$1937923.35 \times C - 4.68$		0.999

*: PP is the photoproduct of the drug.

3. Mathematical Background and Order of Reaction under polychromatic light irradiation

The primary photoreaction, generally labelled $AB(1\Phi)$, involves the phototransformation of a reagent (**A**) into a product (**B**), i.e., $\mathbf{A} \xrightarrow{h\nu} \mathbf{B}$. Despite its simplicity, it is important to notice that, from a reaction photokinetics viewpoint, the primary photoprocess can give rise to two cases in relation to whether or not the photoproduct absorbs the incident light. For the former, the photoproduct is transparent to the light beam used for irradiation of the sample, i.e. the absorptivity of **B** is zero over the range of wavelengths used for irradiation ($\varepsilon_B = 0$). It has been labelled $AB(1\Phi)_{\varepsilon_B=0}$. In the latter kinetic case, **B** absorbs the incident light at the same time as **A**. This photochemical system has the label $AB(1\Phi)_{\varepsilon_B \neq 0}$.

The distinction between these two cases is relevant because their differential equations (rate-laws) are different. This means that the solutions of rate-laws, i.e. the integrated rate-laws, are necessary different. This general principle is also evident, for instance, for thermal reactions where the integrated rate-law of zeroth-order reactions is a linear function whereas that of first-order reactions is described by a mono-exponential function. A variation that stems primarily from the differences occurring in their respective rate-laws.

The aforementioned mathematical principle as well as the analogy with thermal reactions, suggest that the photoreactions $AB(1\Phi)_{\varepsilon_B=0}$ and $AB(1\Phi)_{\varepsilon_B \neq 0}$ kinetic order are expected to be different.

For an $AB(1\Phi)_{\varepsilon_B=0}$ system subjected to a monochromatic light, the closed-form integration of the corresponding rate-law was found to obey a Φ -order kinetics [13].

But the rate-law of the second $AB(1\Phi)_{\varepsilon_B \neq 0}$ photosystem under the same type of light is not possibly integrated in a closed-form (there are no available mathematical methods capable to deriving a solution in a close-form for this non-linear differential equation). A semi-empirical approach has however proposed a working formula for the integrated rate-law of this $AB(1\Phi)_{\varepsilon_B \neq 0}$ whose formulation is typical of Φ -order kinetics with a condition that the final absorbance at the irradiation wavelength does not exceed 0.6 [14].

The case $AB(1\Phi)_{\varepsilon_B=0}$ is very rare for drugs as the spectra of APIs generally overlap those of their photoproducts. From this perspective, the $AB(1\Phi)_{\varepsilon_B \neq 0}$ is more common mechanism in drugs (e.g., NIF and DBZ). However, a closed-form integration of the rate-law of a polychromatic-light driven $AB(1\Phi)_{\varepsilon_B \neq 0}$ photosystems has never been proposed in the literature.

3.1. An integrated rate-law for $AB(1\Phi)_{\varepsilon_B \neq 0}$

The rate-law describing $AB(1\Phi)_{\varepsilon_B \neq 0}$ reactions, when polychromatic light is employed for irradiation (Eq.1), must take into account the wavelength (λ_j) interval spun by the polychromatic excitation light ($\lambda_a \leq \lambda_j \leq \lambda_b$, i.e. $\Delta\lambda = \lambda_b - \lambda_a$).

$$\frac{dC_A(t)}{dt} = - \left(\sum_{\lambda_a}^{\lambda_b} \Phi_{A \rightarrow B}^{\lambda_j} \times \varepsilon_A^{\lambda_j} \times P_0^{\lambda_j} \right) \times l_{\lambda_{irr}} \times F^{\Delta\lambda}(t) \times C_A(t) \quad (1)$$

281 where $C_{A \text{ or } B}(t)$ the concentrations (in M) of **A** or **B** at time t (in s) and $l_{\lambda_{irr}}$ (in cm) is
 282 the optical path length of the collimated irradiation light inside the reactive medium.
 283 The summation is carried out over the product of the photochemical quantum yield of
 284 the primary photoreaction ($\Phi_{A \rightarrow B}^{\lambda_j}$, dimensionless), the radiant power (or intensity) of the
 285 incident light ($P_0^{\lambda_j}$, expressed in *einstein* $dm^{-3} s^{-1}$), and the absorption coefficient of **A**
 286 ($\varepsilon_A^{\lambda_j}$, in $mol^{-1} dm^3 cm^{-1}$). The latter quantities are given here relative to an individual
 287 wavelength, λ_j within the range $\Delta\lambda$.

288 The photokinetic factor, $F^{\Delta\lambda}(t)$ (dimensionless), must take into account the time
 289 dependent, multi-wavelength absorptions ($A_{A \text{ or } B}^{\lambda_j}(t)$) of the light by both reagent (**A**)
 290 and photoproduct (**B**). The total absorbance, in this case, is given by

291

$$292 \quad A_{tot}^{\Delta\lambda}(t) = \sum_{\lambda_a}^{\lambda_b} \left(A_A^{\lambda_j}(t) + A_B^{\lambda_j}(t) \right) = \sum_{\lambda_a}^{\lambda_b} \varepsilon_A^{\lambda_j} \times l_{\lambda_{irr}} \times C_A(t) + \varepsilon_B^{\lambda_j} \times l_{\lambda_{irr}} \times C_B(t) \quad (2)$$

293

294 Where, $F^{\Delta\lambda}(t)$ takes the form

295

$$296 \quad F^{\Delta\lambda}(t) = \frac{1 - 10^{-A_{tot}^{\Delta\lambda}(t)}}{A_{tot}^{\Delta\lambda}(t)} \quad (3)$$

297

The total absorbance, $A_{tot}^{\Delta\lambda}(t)$ in Eq.2, should in practice have a numerical value exceed, by far, unity when $\Delta\lambda$ exceeds a few nanometers. Hence, if $A_{tot}^{\Delta\lambda}(t) \gg 1$ then $10^{-A_{tot}^{\Delta\lambda}(t)} \ll 1$ and $F^{\Delta\lambda}(t)$, considering the mass balance, can be reduced to

$$F^{\Delta\lambda}(t) = \frac{1}{A_{tot}^{\Delta\lambda}(t)} = \frac{\alpha_1^{\Delta\lambda}}{C_A(t) + \alpha_2^{\Delta\lambda}} \quad (4)$$

with $\alpha_1^{\Delta\lambda}$ and $\alpha_2^{\Delta\lambda}$ are both constants (expressed in M) for a given $\Delta\lambda$, and defined as

$$\alpha_1^{\Delta\lambda} = \frac{1}{l_{\lambda_{irr}} \times \sum_{\lambda_a}^{\lambda_b} [\varepsilon_A^{\lambda_j} - \varepsilon_B^{\lambda_j}]} \quad (5)$$

$$\alpha_2^{\Delta\lambda} = C_A(0) \times \frac{\sum_{\lambda_a}^{\lambda_b} \varepsilon_B^{\lambda_j}}{\sum_{\lambda_a}^{\lambda_b} [\varepsilon_A^{\lambda_j} - \varepsilon_B^{\lambda_j}]} \quad (6)$$

By introducing Eq.4 in Eq.1, and rearranging the obtained rate-law to separate the variables, we obtain

$$\frac{C_A(t) + \alpha_2^{\Delta\lambda}}{C_A(t)} dC_A(t) = -\alpha_1^{\Delta\lambda} \times l_{\lambda_{irr}} \times \left(\sum_{\lambda_a}^{\lambda_b} \Phi_{A \rightarrow B}^{\lambda_j} \times \varepsilon_A^{\lambda_j} \times P_0^{\lambda_j} \right) dt \quad (7)$$

Eq.7 can be solved by closed-form integration to yield the integrated rate-law (Eq.8).

$$\left(C_A(t) - C_A(0)\right) + \alpha_2^{\Delta\lambda} \ln \frac{C_A(t)}{C_A(0)} = -\alpha_1^{\Delta\lambda} \times l_{\lambda_{irr}} \times \left(\sum_{\lambda_a}^{\lambda_b} \Phi_{A \rightarrow B}^{\lambda_j} \times \varepsilon_A^{\lambda_j} \times P_0^{\lambda_j} \right) t \quad (8)$$

The latter integrated rate-law (Eq.8) could be presented in much simpler form,

$$\eta(t) = -k_\eta \times t \quad (9)$$

The left-hand side term of the integrated rate-law (Eq.9), combines linear and logarithmic terms has the dimension of a concentration (M).

$$\eta(t) = \left(C_A(t) - C_A(0)\right) + \alpha_2^{\Delta\lambda} \ln \frac{C_A(t)}{C_A(0)} \quad (10)$$

and in its right-hand side term, k_η has the dimension $M s^{-1}$, and is expressed as

$$k_\eta = \frac{\sum_{\lambda_a}^{\lambda_b} \Phi_{A \rightarrow B}^{\lambda_j} \times \varepsilon_A^{\lambda_j} \times P_0^{\lambda_j}}{\sum_{\lambda_a}^{\lambda_b} \left[\varepsilon_A^{\lambda_j} - \varepsilon_B^{\lambda_j} \right]} \quad (11)$$

3.2. The kinetic order of the polychromatic-light driven $AB(1\Phi)_{\varepsilon_B \neq 0}$ photoreaction

The simple formulation of the integrated rate-law (Eq.9), with its coefficients (Eqs.10 and 11), does not compare to any known integrated rate-laws proposed, to date, in kinetics. The $\eta(t)$ expression (Eq.10) is a mixture of a zeroth-order kinetics (the linear section), and a first-order kinetics (the logarithmic section). Whereas, the k_η constant has a dimension of a zeroth-order reaction. Such a combination of kinetic orders in one formula has never been observed before for a single reaction.

The dimension of k_η can be thought as a strong argument to consider it as a rate-constant for the $AB(1\Phi)_{\varepsilon_B \neq 0}$ photoreaction. In its form, Eq.11 indicates that the numerical value of k_η should increase with quantum yield and radiant power. A specific property of photoreactions that has also been identified for the photoreaction's rate-constant obeying a pure Φ -order kinetics ($AB(1\Phi)_{\varepsilon_B=0}$ under monochromatic-light irradiation [13,14]).

Accordingly, Eq.9 describes the particular kinetic behaviour of $AB(1\Phi)_{\varepsilon_B \neq 0}$ photoreactions, and hence, defines a new reaction order: the η -kinetic order.

As a characterisation of η -order kinetics, let us look at some of its properties.

- (i) the applicability of η -order kinetics is limited to the linearity range of the calibration graph built using the variation of $A_{tot}^{\Delta\lambda}$. In the case, $\sum_{\lambda_a}^{\lambda_b} \varepsilon_A^{\lambda_j} > \sum_{\lambda_a}^{\lambda_b} \varepsilon_B^{\lambda_j}$, a calibration graph according to Eq.12 is sufficient. Otherwise, $(\sum_{\lambda_a}^{\lambda_b} \varepsilon_A^{\lambda_j} < \sum_{\lambda_a}^{\lambda_b} \varepsilon_B^{\lambda_j})$ a similar calibration graph to Eq.12 should be built for the photoproduct alone (n , in Eq.12, being the number of different initial concentrations used for the calibration graph).

$$A_A^{\Delta\lambda,n}(0) = \left(\sum_{\lambda_a}^{\lambda_b} \varepsilon_A^{\lambda_j} \times l_{\lambda_{irr}} \right) \times C_A^n(0) \quad (12)$$

(ii) point (i), generally imposes that the initial concentration of the reactant is relatively low. The Beer-Lambert law, which only applies over the linearity range of the calibration graph, discourages the use of high concentrations of the photoreactant.

(iii) k_η is independent of the initial concentration of reactant **A**

(iv) k_η is dependent on the irradiation wavelength interval

(v) k_η is independent of the optical path length of irradiation ($l_{\lambda_{irr}}$)

(vi) k_η is proportional to $\Phi_{A \rightarrow B}^{\lambda_j}$, and $P_0^{\lambda_j}$

(vii) The half-life time ($t_{1/2}$ in s), defined by Eq.13, is not only dependent on the initial concentration ($C_A(0)$) of the reactant (**A**) but also on all the attributes of the photochemical reaction, including the absorptivities of both reagents (**A** and **B**), and $\Delta\lambda$. At constant $C_A(0)$, $t_{1/2}$ is expected to decrease with increasing radiant power. $t_{1/2}$ is proportional to $C_A(0)$.

$$t_{1/2} = \frac{0.5 \times C_A(0) + \alpha_2^{\Delta\lambda} \ln 2}{k_\eta} \quad (13)$$

(viii) The initial velocity of the reactant's reaction ($r_{0,A}^\eta$ in $M s^{-1}$), given by Eq.14, is obtained from Eq.1. It has similar dependencies on the reaction attributes as k_η , e.g., $r_{0,A}^\eta$ increases with increasing radiant power. It is

expected to be independent of the initial concentration if the term $(1 - 10^{-A_{tot}^{\lambda}(0)})$ is equal to unity when $A_{tot}^{\Delta\lambda}(0) \gg 1$.

$$r_{0,A}^{\eta} = \left[\frac{dC_A(t)}{dt} \right]_{t=0} = -C_A(0) \times k_{\eta} \times l_{\lambda_{irr}} \times \sum_{\lambda_a}^{\lambda_b} [\varepsilon_A^{\lambda_j} - \varepsilon_B^{\lambda_j}] \times F^{\Delta\lambda}(0) \quad (14)$$

(ix) Finally, it is important to underline that the $AB(1\Phi)_{\varepsilon_B \neq 0}$ photoreaction undergoes a true changes of kinetic order depending on the type of light employed. $AB(1\Phi)_{\varepsilon_B \neq 0}$ systems obey pure first-order kinetics if they are subjected to isosbestic monochromatic light. They follow a pure Φ -order kinetics when the irradiation light is monochromatic but non-isosbestic. These reactions obey η -order kinetics if the light driving the phototransformation is polychromatic.

4. Results and discussion

4.1. The photokinetics of DBZ and NIF under monochromatic light

Photodegradations of both drugs under monochromatic light irradiation performed in ethanol solutions were previous reported [14,15]. It was established therein that each drug underwent a purely unimolecular photoreactions yielding its corresponding, single photoproduct (either NIF-PP or DBZ-PP). These reactions are typical $AB(1\Phi)_{\varepsilon_B \neq 0}$. The electronic absorption spectra of reactant and photoproduct overlapped on a large section of the absorption domain except for the long wavelength

UVA-Vis region. The data collected on their respective photodegradations showed that these drugs obeyed Φ -order kinetics.

It was also demonstrated that the quantum yields of their respective phototransformations were wavelength-dependent following sigmoid trends (the highest values of the quantum yield were situated towards the higher wavelengths). The quantum yield values of DBZ and NIF over $\Delta\lambda$ will be used for our investigation of the polychromatic light irradiation of these drugs.

Extra experiments have confirmed the predictions of the mathematical Φ -order model [14-15]: on one hand, a well quantified self-photostabilisation was induced by increasing initial reactant concentration, and on the other hand, a significant improvement of drug photoprotection was quantified in the presence of absorption competitors.

4.2. Spectral features of DBZ and NIF under polychromatic light

Qualitatively the changes observed on the electronic spectra the drugs during polychromatic light exposure (Fig.2) were very similar to those induced by monochromatic irradiation [14,15]. Incidentally, such a similarity meant that it is not possible to know, from the kinetic traces, which type of irradiation was used to drive the photoreactions (implying that the characterisation of a monochromatic light can only be achieved by instrumentation, e.g., monochromators).

Figure 2. Evolution of the absorption spectra of (a) NIF (2.67×10^{-5} M) and (b) DBZ (5.41×10^{-5} M) in ethanol, when subjected to a polychromatic irradiation (200 – 400 nm) using a mixed-wavelength lamp (254/365 nm, Fig.1). Arrows indicate direction of absorbance change; vertical lines cross the spectra at the isosbestic points.

The mechanism in play for both drugs does not change due to the nature the irradiation light (poly- or monochromatic), as confirmed by the occurrence of a single photoproduct, for each drug, identified by HPLC over reaction times.

The progress of the photoreaction is evidenced by a reduction in absorbances of the lowest-energy $\pi \rightarrow \pi^*$ electronic absorption bands, and an increase of most of the remaining transitions. The clearly identified isosbestic points indicate smooth drugs' photodegradation with no measurable presence of by-products (Fig.2). Little evolution of the spectra is recorded at the end of the reactions indicating that the reactant-drug (either NIF or DBZ) has been fully depleted.

The last electronic spectrum recorded at the end of the reaction ($t = \infty$), corresponds therefore, to that of the photoproduct. The measured total absorptions coefficients of **A** and **B** ($\sum_{\lambda_a}^{\lambda_b} \varepsilon_A^{\lambda_j}$ and $\sum_{\lambda_a}^{\lambda_b} \varepsilon_B^{\lambda_j}$) are 1150028.96 and 344785.15 M⁻¹ cm⁻¹, and 1920219.56 and 1936173.24 M⁻¹ cm⁻¹ for the pairs DBZ/DBZ-PP and NIF/NIF-PP, respectively. Notice that the former values for the spectra of DBZ show that $\sum_{\lambda_a}^{\lambda_b} \varepsilon_B^{\lambda_j}$ (i.e., of DBZ-PP) is much smaller than that of DBZ. This is not the case for NIF whose total absorption coefficient is practically the same as that of its photoproduct (less than 0.9% difference, which was also later confirmed from their calibration graphs, Table 1). This means that in both cases a calibration graph of the reactant is sufficient for our study.

4.3. Kinetics of the drugs under polychromatic light

The irradiation of the ethanolic solutions of both drugs has been performed by a mixed-wavelength lamp (Lamp #4) that has emissions at both 254 nm and over the 310 – 400 nm range (Figs.1 and 3). The span of the light supplied by this lamp, overlaps the regions of electronic absorption of both drugs.

Figure 3. Absorption coefficients of initial drug (ϵ_A) and its photoproduct (ϵ_B) for (a) DBZ and (b) NIF, the mixed (254/365 nm) wavelength light-profile of the irradiation lamp, and the sigmoid patterns of the photochemical reactions' quantum yields [14,15].

The increasing quantum yields with wavelength (Fig.3) indicate that both drugs are more photodegradable with UVA rather than with UVB. Overlapping this data with Lamp #4 profile and absorption spectra of the species, makes it evident that most photoreactivity will be due to the reactant molecule transforming under UVA/VIS light (the UVB light of Lamp #4 occurring mainly at 254 nm, would only have a marginal contribution). Such an analysis of the data is mandatory to explain and understand the kinetic behaviour of drugs under polychromatic light (a further analysis is presented in section 4.5).

Timely irradiations of the samples with polychromatic light causes a smooth decrease of the long-wavelength electronic bands (Fig.2). HPLC analysis confirmed that the photoproducts are photochemically stable, at least, for longer times than the experiments' durations.

The kinetic traces, recorded at maximum absorbance wavelengths, suggest a fast photodegradation in the early stages (<15 min) is followed by a more curved pattern

at later times, in full agreement with the predictions of the η -order kinetics model (Eqs.9, and 10).

The experimental data from these traces, of both drugs, were well described by the η -order kinetic model (Eq.9), with $\eta(t)$ values obtained for different concentrations, evolve according to linear relationships with photoreaction time (Fig.4).

Qualitatively, the experimental overall rate-constants (k_η), corresponding to the gradient of η -order kinetics, $\eta(t) = k_\eta t$, and performed in the same experimental conditions for both drugs, are higher for NIF than for DBZ ($k_{\eta,NIF}^{Lamp\#4} > k_{\eta,DBZ}^{Lamp\#4}$, Fig.4). NIF, is hence, much more photodegradable than DBZ under irradiation by the same mixed-wavelength Lamp #4. A finding that corroborates the relative photoreactivity of these drugs under monochromatic light, according to the ranking scale that was established based on each drug's range of its β -factor over its absorption region [15-20]. This scale was thought to set the foundation for a database on photoactive drugs.

For NIF and DBZ the β -factor values ($2121 \leq \beta_{DBZ} \leq 4013$ and $8117 \leq \beta_{NIF} \leq 9776 \text{ M}^{-1} \text{ s}$) attested of a much higher reactivity of NIF compared to DBZ (in that classification, NIF and DBZ belong to group II and III, respectively [19-20]).

Figure 4. Linear η -order correlations (according to Eq.9) for the experimental photokinetic traces of (a) DBZ and (b) NIF, measured at various initial concentrations and exposed to Lamp #4.

The overall rate-constants (k_η) could then play, for polychromatic light, the same role played by β -factor for monochromatic light. Such a scale, starting here with the k_η values of these two drugs under Lamp #4, would be very useful to inform about drugs photoreactivity with regard to light type (the usefulness of such a scale is also relevant to actinometry, as described further in section 4.5).

4.4. *The effect of initial concentration of DBZ and NIF on photodegradation*

In previous studies [14,20,39,40], the effect of initial concentration on Φ -order kinetics was considered for strictly monochromatic-light irradiation. It was experimentally shown that the rate-constant of the photoreaction decreases with increasing initial concentration for the direct reaction $AB(1\Phi)_{\varepsilon_B \neq 0}$ as in the cases of NIF [14] and Nisoldipine [39], and predicted for the photoreversible $AB(2\Phi)$ [40] and multi-consecutive $AB_4(4\Phi)$ [20] reactions as indicated by the corresponding formulae of the respective rate-constants. Incidentally, the overall rate-constant of the pure primary photoreaction, $AB(1\Phi)_{\varepsilon_B=0}$ [13], does not depend on initial concentration of the reactant.

These findings strongly suggest that the initial concentration of the reactant might have a significant impact on the kinetic rates of photoreactions. Thus far however, there are no systematic proofs in the literature on how $C_A(0)$ affects the overall reactivity when the irradiating beam is a polychromatic light.

For the present study, the effect of increasing initial concentrations of DBZ and NIF has been investigated in the respective ranges $1.5 - 10.5 \times 10^{-5}$ M, and $1.5 - 16.1 \times 10^{-5}$ M (Fig.5).

Figure 5. Photokinetic traces of (a) DBZ and (b) NIF under polychromatic light using the mixed-wavelength lamp #4 (254/365 nm). The experimental data (circle) were determined by HPLC.

The η -order kinetic formulae (Eqs.9-11) allowed the determination of the individual η -order overall rate-constants (k_η) and initial velocities (r_0^η) for each kinetic trace recorded for NIF and DBZ. An excellent correlation (less than 5% error) was found between these experimental values and the ones independently calculated using Eqs.11 and 14. Such an agreement of experimental and calculated values for k_η or r_0^η , is a solid confirmation of the validity of the mathematical η -order kinetics model, proposed here for $AB(1\Phi)_{\varepsilon_B \neq 0}$ phototransformations, since the data used for the calculated values and those of the experimental ones belong to separate studies involving different radiation conditions [14,15].

Representing of k_η or r_0^η against initial reactant concentration proved the invariance of both these quantities with initial concentration of the drugs (Fig.6, Eqs.11, and 14); in an obvious contradiction to what has been predicted and observed for monochromatic light irradiation. Hence, with regard to the variation of initial concentration, an $AB(1\Phi)_{\varepsilon_B \neq 0}$ reaction adopts different behaviours depending on the type of light used (mono- or polychromatic). Practically, this means that the initial concentration does not affect the η -order kinetics of either NIF or DBZ. Nonetheless,

Figure 6. Invariance of $k_{\eta,\text{exp.}}$ and $r_{0,\text{exp}}^\eta$ for (a) DBZ and (b) NIF with different initial concentrations ($C_A(0)$). The solid symbols correspond to the calculated values of $k_{\eta,\text{cld.}}$ and $r_{0,\text{cld.}}^\eta$.

this conclusion is valid as long as the Beer-Lambert law is also valid, i.e. $C_A(0)$ must fall within the linearity range of the drug's calibration graph.

4.5. Methodology to devising new drug-actinometers for $AB(1\Phi)_{\varepsilon_B \neq 0}$ systems under polychromatic light

The potential of DBZ and NIF for polychromatic light actinometry is tested by subjecting freshly prepared solutions of given concentration ($2.3 \times 10^{-5} \text{ M}$ and $2.69 \times 10^{-5} \text{ M}$, respectively, in ethanol) to varying total intensities of the polychromatic light ($P_{0,\text{tot}}^{\Delta\lambda} = \sum_{\lambda_a}^{\lambda_b} P_0^{\lambda_j}$) emitted by the mixed-wavelength range lamp (Lamp #4). Total (over $\Delta\lambda$) instead of individual (at each λ) light intensity of the lamp is used here, to conform with the generally procedure adopted in actinometry. The photokinetic experimental traces for each irradiation (" q " at $P_{0,\text{tot}}^{\Delta\lambda,q}$) were constructed based on HPLC measurements of the reactant concentrations. These traces were analysed according

559 to η -order kinetics (Eq.9) and the experimental $k_{\eta,q}$ values corresponding to each
 560 individual total light intensity $P_{0,tot}^{\Delta\lambda,q}$, were determined.

561 A perfectly linear relationships linked variations of the overall rate-constant and the
 562 total light intensity for both investigated drugs with relatively high ($r > 0.99$) correlation
 563 coefficients of the lines, with intercepts close to zero (Fig.7). The experimentally
 564 constructed graphs in Fig.7 conform well to the principle predicting an increasing
 565 photoreactivity with light intensity as expected for k_{η} (see above point (vi)). Nonetheless,
 566 such a correlation might come as a surprise, because such a linear trend is not obvious
 567 from the formula of k_{η} (Eq.11, which explicitly depends on individual $P_0^{\lambda_j}$). In fact, since
 568 Eq.11 predicts that a specific value of $k_{\eta,q}$ will correspond to a given irradiation with
 569 total $P_{0,tot}^{\Delta\lambda,q}$, Eq.11 can be re-written for that purpose, as linear relation of $k_{\eta,q}$ and $P_{0,tot}^{\Delta\lambda,q}$
 570 for any Lamp (Eq.15). The β_{η} factor is a constant when $P_{0,tot}^{\Delta\lambda,q}$ varies for given
 571 experimental conditions and reactive system (i.e., the ratio $\sum_{\lambda_a}^{\lambda_b} (\Phi_{A \rightarrow B}^{\lambda_j} \varepsilon_A^{\lambda_j} P_0^{\lambda_j}) / \sum_{\lambda_a}^{\lambda_b} P_0^{\lambda_j}$
 572 in Eq.15 is invariant with change of the light intensity of the lamp).

573

$$574 \quad k_{\eta,q} = \frac{\sum_{\lambda_a}^{\lambda_b} \Phi_{A \rightarrow B}^{\lambda_j} \times \varepsilon_A^{\lambda_j} \times P_0^{\lambda_j}}{P_{0,tot}^{\Delta\lambda,q} \sum_{\lambda_a}^{\lambda_b} [\varepsilon_A^{\lambda_j} - \varepsilon_B^{\lambda_j}]} P_{0,tot}^{\Delta\lambda,q} = \beta_{\eta,Drug}^{Lamp \#4} P_{0,tot}^{\Delta\lambda,q} \quad (15)$$

575

576 According to Eq.15, the gradients of the lines in Fig.7, represent the coefficients
 577 $\beta_{\eta,DBZ}^{Lamp \#4}$ and $\beta_{\eta,NIF}^{Lamp \#4}$ of the drugs for the employed Lamp #4. The fact that $\beta_{\eta,NIF}^{Lamp \#4}$ is
 578 almost 6.5-fold higher than $\beta_{\eta,DBZ}^{Lamp \#4}$ (respectively, 1365 and 211 M⁻¹s, Fig.7), clearly
 579 indicates that NIF photodegradation under Lamp #4 is faster than that of DBZ. Also,

Figure 7. Linear correlations between experimental values of the overall rate-constant (k_{η}) and the total radiant power ($P_{0,tot}^{\Delta\lambda}$) of Lamp #4 for DBZ and NIF in ethanolic solutions (2.3 and 2.69×10^{-5} M, respectively) at room temperature.

owing to the invariance of k_{η} with initial concentration (Section 4.4.), the same behaviour and these values of β_{η} factors should be expected irrespective of the initial concentration of the drugs.

A strong evidence for reliability of the η -order kinetics model comes from the calculated coefficients $\beta_{\eta,drug}^{Lamp \#4}$ using Eq.15 and the experimental attributes including individual wavelength quantum yield values determined in previous investigations [14,15]. For both investigated drugs, less than 5 % variation was recorded between these calculated $\beta_{\eta,cld.,drug}^{Lamp \#4}$ and the experimental ($\beta_{\eta,exp.,drug}^{Lamp \#4}$) ones.

The latter finding is paramount, because it proves unnecessary the experimental actinometric measurements for $AB(1\Phi)_{\varepsilon_B \neq 0}$ systems under polychromatic irradiation. Indeed, it implies that whenever individual-wavelength attributes are available for actinometers, actinometric reaction and lamp, the actinometric behaviour under

polychromatic light of the given lamp, can surely and easily be calculated from Eq.15, with no need to actually performing the corresponding experiments. A considerable advantage in the field, that underlines another benefit of a detailed wavelength study of the photoreaction under monochromatic light. Incidentally, a very early prediction [14], has foreseen the determinant involvement of such monochromatic-light data in the modelling of polychromatic kinetics.

Fig.7 also confirms that the photokinetic behaviour of actinometers is intimately impacted by both their intrinsic photochemical and spectrophotometric features, even when they are irradiated by the same lamp (Eq.15).

Also obvious from Fig.7, that individual measurements of the rate-constant k_η have to be considered specific to the experiment at hand, because as such they cannot allow drawing general conclusions about the reactivity of the species (only the β factors can allow this type of conclusions, as above seen $\beta_{\eta,NIF}^{Lamp\ #4} > \beta_{\eta,DBZ}^{Lamp\ #4}$). For instance, an individual k_η value of DBZ can well be higher than that of NIF if the light intensity impinging on the former is higher than that shone on the latter (e.g., $k_{\eta,DBZ} = 0.0265\ M s^{-1}$ ($P_{0,tot}^{\Delta\lambda,DBZ} = 34.7\ 10^{-5}\ M\ s^{-1}$) and $k_{\eta,NIF} = 0.0158\ M s^{-1}$ ($P_{0,tot}^{\Delta\lambda,NIF} = 2.7\ 10^{-5}\ M\ s^{-1}$); however, always $k_{\eta,NIF} > k_{\eta,DBZ}$ if the light intensity is the same).

Now, in terms of using these drugs as actinometers, the following procedure can be adopted. This actinometric method is developed here for DBZ and NIF but can be extended to any photosystem of the $AB(1\Phi)_{\varepsilon_B \neq 0}$ type. The purpose of this method is the determination of the unknown total light intensity of a Lamp X. it can be summarised in two major (A and B) steps:

619 -(A) the actinometer-drug is calibrated with Lamp X. The drug is calibrated using
620 various known intensities of Lamp X. The $\beta_{\eta,drug}^{Lamp X}$ is determined in a similar way
621 presented above (Fig.7). $\beta_{\eta,drug}^{Lamp X}$ is archived for actinometric purposes in future
622 experiments. For the instance of lamp #4, the $\beta_{\eta,drug}^{Lamp \#4}$ factors, determined in the
623 present study of the drugs, can be used without a need for re-measurements, as
624 proposed in this (A), if the conditions of the experiment are the same. This, however,
625 is not easy to achieve between different laboratories, and so recalibration is most often
626 necessary (using step B).

627 -(B) the selected actinometer-drug is used to determine an unknown light intensity of
628 Lamp X, $P_{0,tot}^{\Delta\lambda,unk}$. The actinometer sample is irradiated by Lamp X, as for the
629 investigated reaction of interest.

630 The detailed procedure can be performed according to the following chart.

631 (act-1) prepare a fresh solution of either DBZ or NIF in ethanol at a
632 concentration between $1.5 - 10.5 \times 10^{-5}$ M and $1.5 - 16.1 \times 10^{-5}$ M, respectively.

633 (act-2) irradiate the sample with Lamp X at a known light-intensity value, $P_{0,tot,i}^{\Delta\lambda}$.

634 Record the kinetic trace until no more variation is detected on the absorption
635 spectrum, and on the HPLC chromatogrammes.

636 (act-3) use the previous data to calculate the corresponding value for $\eta_i(t)$

637 (act-4) draw $\eta_i(t) = -k_{\eta,i} \times t$, for the data at hand (the graph should be a
638 straight line).

639 (act-5) determine the value of k_{η_i} as the gradient of the previous line (act-4).

(act-6) repeat steps (act-2) to (act-5) using n ($3 < i = n$) different light intensities of the same lamp, irradiating the sample at the same selected concentration.

(act-7) draw $k_{\eta,i} = \beta_{\eta,drug}^{Lamp X} \times P_{0,tot,i}^{\Delta\lambda}$ and determine the value of the gradient $\beta_{\eta,drug}^{Lamp X}$ as a reference value for this actinometer.

(act-8) subject a fresh sample of the actinometer, as the ones used previously, to irradiation from Lamp X, with currently unknown intensity $P_{0,tot}^{\Delta\lambda,unk}$, used for the actual experiment.

(act-9) determine the value of $k_{\eta,unk}$. as described in (act-2) to (act-5).

(act-10) calculate the unknown total light intensity of Lamp X, $P_{0,tot}^{\Delta\lambda,unk}$, for the actual experiment, using Eq.16.

$$P_{0,tot}^{\Delta\lambda,unk} = \frac{k_{\eta,unk}}{\beta_{\eta,drug}^{Lamp X}} \quad (16)$$

These examples of DBZ and NIF actinometers are recommended to amend the Q1b ICH document [4] as alternatives to the quinine hydrochloride actinometer. The usefulness of the latter for reliable actinometry in pharmaceuticals has been questioned by a number of studies [41-43].

4.6. Are $AB(1\Phi)_{\varepsilon_B \neq 0}$ photosystems universal actinometers?

Actinometers are usually supposed to be universal. Universality here means that the actinometric data obtained for a given actinometer, on one particular lamp, is useful to determine the total light intensity of any other lamp. This is why the actinometers

proposed in the literature, even though they have, most often, been calibrated against a single lamp, they are supposed to be useful to directly determine the unknown intensity of any other lamp. This is the case for the ICH recommended actinometer, the quinine hydrochloride [4], and the much more popular ferrioxalate actinometer. Nonetheless, the above definition of “actinometer universality”, has never been validated by strong experimental evidence.

To test the hypothesis of universality of actinometers, let us consider the photoconversion of NIF under irradiation by different lamps.

For this study we selected 4 different lamps (Fig.1) whose emissions overlap only small sections of the wavelength range 200 – 400 nm, namely, (#1) short-wavelength lamp 254 nm, (#2) mid-wavelength lamp 302 nm, (#3) long-wavelength lamp 365 nm and (#4) mixed-wavelength lamp with a filter for visible light 254/365 nm. Each lamp was used to perform a full actinometric study as described in the previous section. Identical total radiant powers ($P_{0,tot}^{\Delta\lambda,Lamp\#i}$) from the different lamps were also provided

Figure 8. Linear relationships obtained for NIF (2.69×10^{-5} M in ethanol) between the overall rate constants, k_{η} , measured for various lamps intensities and the corresponding total radiant power, $P_{0,tot}^{\Delta\lambda}$, for the four lamps (Lamp #1 - Lamp #4, Fig.1).

Table 2. Correlation features of NIF overall rate-constant, k_{η} , with the total radiant power, $P_{0,tot}^{\lambda}$, for the four lamps used in this study (Fig.1).

Lamp # i	Line equation $k_{\eta}^{Lamp \#i} = \beta_{\eta,NIF}^{Lamp \#i} \times P_{0,tot}^{\Delta\lambda,Lamp \#i} + \text{intercept}$	r^2
1	$548.26 P_{0,tot}^{\Delta\lambda,Lamp \#1} - 0.4 \cdot 10^{-3}$	0.99
2	$1109.8 P_{0,tot}^{\Delta\lambda,Lamp \#2} + 1.2 \cdot 10^{-3}$	0.99
4	$1365.3 P_{0,tot}^{\Delta\lambda,Lamp \#3} + 1.3 \cdot 10^{-3}$	0.99
3	$779.26 P_{0,tot}^{\Delta\lambda,Lamp \#4} + 1.5 \cdot 10^{-3}$	0.99

for the irradiation of NIF samples. The $\beta_{\eta,NIF}^{Lamp \#i}$ factors were determined for each lamp separately as shown in Fig.8 (and Table 2).

It is evident that the different lamps have different effects on the photokinetics of NIF. The highest rate of photodegradation was observed for Lamp #4 ($\beta_{\eta,NIF}^{Lamp \#4} = 1365.3$) and the lowest for lamp #1 ($\beta_{\eta,NIF}^{Lamp \#1} = 548.3$). These can be explained by the emission range of the lamp relative to the absorption spectrum and quantum yield of NIF (Figs.1 and 3). Accordingly, the main emission region of the short wavelength lamp (~254 nm) corresponding to the lowest section of NIF quantum yield sigmoid (200 – 275 nm, Fig.3), explains well the lowest β_{η} factor value recorded for this Lamp #1. The remaining light sources profiles overlap the highest quantum yield region. Lamp #4 profile (325 – 400 nm) covers almost fully the higher quantum yield section (300 – 400 nm, Fig.3), compared to Lamps #2 and #3. Lamp #4 records the highest β_{η} value. However, the last two lamps (#2 and #3) are not that evident to rank within the set. If the profile of Lamp #2 overlaps a 100 nm of the quantum yield sigmoid, Lamp #3,

698 overlaps ca. 60 nm of the sigmoid plateau region (350 – 400 nm, Fig.7) corresponding
699 to the highest quantum yield values.

700 Since such a qualitative analysis cannot help to rank Lamps #2 and 3, then let us
701 use the η -order model. The sum of products, the $\sum(\Phi \varepsilon P)$ term, in the rate-constant
702 formula (Eq.15), easily explains the difference in k_η values that are recorded for either
703 changing species that are irradiated with the same lamp (Fig.7), or changing lamp
704 profiles for the same species (Fig.8). It is, in both cases, highly unlikely that the sums
705 ($\sum(\Phi \varepsilon P)$) be equal. For instance, the quantitative interpretation offered above for the
706 ranking of Lamps #2 and #4 k_η values, are predicted by Eq.15.

707 For Lamps #2 and 3, Eq.15 can give an interpretation of the difference in their
708 experimental k_η values. Indeed, let us first note that the lamp profile #3 coincides with
709 a spectral region where practically only the reactant absorbs, whereas, Lamp #2
710 emission spans both reactant and photoproduct absorption regions, specially over the
711 275 – 350 nm section. The denominator of Eq.15 increases with the difference
712 between the total absorbances, $\sum(\varepsilon_A - \varepsilon_B)$, of reactant and photoproduct. Therefore,
713 k_η and hence $\beta_{\eta,NIF}^{Lamp \#i}$ decreases as $\sum(\varepsilon_A - \varepsilon_B)$ tends to its maximum value, $\sum \varepsilon_A$.
714 Accordingly, Eq.11 predicts that the overall rate-constant values for Lamp #3 (where
715 almost only the reactant absorbs, $\sum \varepsilon_B \cong 0$) should most likely be lower than that of
716 Lamp #2. Therefore, we reconstitute the correct experimental order of $\beta_{\eta,NIF}^{Lamp \#i}$ values
717 (Fig.8).

718 The above discussion confirms the validity of η -order equations but does not tell
719 whether the NIF-actinometer is universal. For this let us consider the scenario where

720 NIF-actinometry was developed on a particular lamp (let it be Lamp #4 with $\beta_{\eta,NIF}^{Lamp\ #4}$
721 its constant, Table 2) and the test lamp could be any of the set (Lamp #1 to #4).

722 Obviously, if the test lamp is #4 then there are no issues and the unknown intensity
723 could be worked out as described in the above procedure (act-10).

724 More interestingly, is the case when the test lamp is different from #4 (let it be
725 Lamp #2). The question here is whether the unknown intensity of Lamp #2 can be
726 precisely determined by exposing our NIF-actinometer sample to this lamp, and
727 determining its unknown light intensity using an earlier calibration performed on Lamp
728 #4.

729 Let us consider that the overall rate-constant recorded experimentally for NIF with
730 the test lamp (#2) is, for instance, $k_{\eta,\#2} = 0.332\ M\ s^{-1}$. The corresponding light
731 intensity of this $k_{\eta,\#2}$ value on Lamp #4 calibration is $P_{0,tot,cld.}^{\Delta\lambda,Lamp\ #4} = 2.42\ 10^{-4}\ M\ s^{-1}$. The
732 latter value ($2.42\ 10^{-4}\ M\ s^{-1}$) is supposedly expressing the total light intensity received
733 by NIF from Lamp #2 (whose kinetics is characterised by $k_{\eta,\#2} = 0.332\ M\ s^{-1}$). This is
734 not correct since the latter value ($k_{\eta,\#2}$), on the specific calibration of Lamp #2 (Fig.8,
735 Table 2), corresponds to a total intensity of light, $P_{0,tot}^{\Delta\lambda,Lamp\ #2} = 2.98\ 10^{-4}\ M\ s^{-1}$. This
736 clearly means that there is a difference of ca.19% between the true value of the total
737 light intensity inducing the reaction (Lamp #2, $k_{\eta,\#2}$ and $P_{0,tot}^{\Delta\lambda,Lamp\ #2}$), and that worked
738 out from the Lamp #4-based actinometry (Lamp #4, $k_{\eta,\#2}$ and $P_{0,tot}^{\Delta\lambda,Lamp\ #4}$). A Similar
739 situation arises if one of the other lamps (#1 or #3) is used instead of Lamp #2.

740 Therefore, one is forced to accept that it is simply not possible to work out the
741 correct $P_{0,tot}^{\Delta\lambda,Lamp\ #i}$ ($i \neq j$) from that of an actinometer that was calibrated on Lamp #j
742 (for our example $i = \#4$ and $j = \#1, \#2$ or $\#3$).

743 Accordingly, NIF is not a universal actinometer. It is necessary to use it as an
744 actinometer only for the lamp it was calibrated with.

745 A finding that makes up an experimental proof stating that polychromatic-light
746 actinometers cannot be universal. Each actinometer/lamp pair must be calibrated
747 individually, i.e., for a given actinometer, there are as many calibration methods
748 required as there are light sources. This has been proven here for $AB(1\Phi)_{\varepsilon_B \neq 0}$
749 systems, but in principle, should be true for all actinometers. Therefore, the working
750 principle should, indeed, become “actinometry and actinometers are lamp-specific”.

751 Since, the conditions of irradiation vary from lab to lab (size of the irradiated
752 sample area and sample volume), then it would be recommended to develop the
753 actinometric method on site using the procedure (act-1 and act-10).

5. Concluding remarks and perspectives

Our experimental results for NIF and DBZ actinometries confirm that can be proposed as reliable actinometers for the UVA range of polychromatic light sources, and alternatives to the ICH Q1b actinometer. NIF and/or DBZ actinometry will provide reliable and more accurate measurements for pharmaceutical photostability studies. The low concentrations needed for such actinometry reduces considerably the cost of these methods. They also open a venue to recruiting more $AB(1\Phi)_{\varepsilon_B \neq 0}$ drug-actinometers to allow widening the spectral range covered.

The η -order kinetics is proven to be the best way available today to describe $AB(1\Phi)_{\varepsilon_B \neq 0}$ reactions when exposed to polychromatic light. In this context, the classical kinetic (0th-, 1st- and 2nd-) orders become, *de facto*, invalid for this type of reactions and undoubtedly lead to incorrect results and conclusions.

A new perspective in photokinetics and actinometer emerges from the present study, that is, rate-laws, integrated rate-laws are both mechanism and light condition specific which leads actinometry to being both lamp profile and actinometer, specific.

References

1. Albini, A.; Fasani, E. (Eds.) *Drugs, Photochemistry and Photostability*; Royal Society of Chemistry: London, UK, 1998.
2. Tønnesen, H.H. *Photostability of drugs and drug formulations*. 2nd ed. London: CRC Press, UK, 2004.
3. Piechocki, J.T.; Thoma, K. *Pharmaceutical Photostability and Stabilization Technology*; *Drugs and the Pharmaceutical Sciences*; CRC Press: Boca Raton, FL, USA, 2006.
4. U.S. Food and Drug Administration. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Photostability Testing of New Drug Substances and Products Q1B. *Fed. Regist.* 1997, 62, 27115–59857.
5. ICH(S10), ICH Harmonised Tripartite Guideline Photosafety Evaluation of pharmaceuticals S10, 2013. Available at: http://www.ich.org/fileadmin/public/Web_Site/ICH_Products/Guidelines/Safety/S10/S10_4.pdf.
6. Her Majesty's Stationery Office, *British Pharmacopoeia*, Her Majesty's Stationery Office, London, UK, 2020.
7. United States Pharmacopeial Convention, *United States Pharmacopeia 29*, United States Pharmacopeial Convention, Rockville, Md, USA, 2012.
8. Ahmad, I.; Ahmed, S.; Anwar, Z.; Sheraz, M.A.; Sikorski, M. Photostability and Photostabilization of Drugs and Drug Products. *Int. J. Photoenergy*. **2016**, 1.
9. De Luca, M.; Ioele, G. ; Ragno, G. 1,4-Dihydropyridine Antihypertensive Drugs: Recent Advances in Photostabilization Strategies. *Pharmaceutics*. **2019**, 11, 85.
10. Kryczyk-Poprawa, A.; Kwiecien A.; Opoka, W. Photostability of Topical Agents Applied to the Skin: A Review. *Pharmaceutics*. **2019**, 12, 10.
11. Challis, J.K.; Hanson, M.L.; Friesen, K.J.; Wong, C.S. A critical assessment of the photodegradation of pharmaceuticals in aquatic environments: defining our current

- understanding and identifying knowledge gaps. *Environ. Sci. Processes Impacts*, **2014**, 16, 672-696.
12. Trawiński, J.; Skibiński, R. Studies on photodegradation process of psychotropic drugs: a review. *Environ. Sci. Pollut. Res.* **2017**, 24, 1152–1199.
13. Maafi, M.; Brown, R.G. The kinetic model for AB(1 Φ) systems. Aclosed-form integration of the differential equation with a variable photokinetic factor. *J. Photochem. Photobiol. A Chem.* **2007**, 187, 319-324.
14. Maafi, W.; Maafi, M. Modelling nifedipine photodegradation, photostability and actinometry properties. *Int. J. Pharm.* **2013**, 456, 153-164.
15. Maafi, M.; Lee, L.-Y. Determination of Dacarbazine Φ -order photokinetics, quantum yields, and potential for actinometry. *J. Pharm. Sci.* **2015**, 104, 3501-3509.
16. Maafi, M.; Maafi, W. Φ -order kinetics of photoreversible-drug reactions. *Int. J. Pharm.* **2014**, 471, 536-543.
17. Maafi, M.; Maafi, W. Montelukast photodegradation: elucidation of Φ -order kinetics, determination of quantum yields and application to actinometry. *Int. J. Pharm.* **2014**, 471, 544-552.
18. Maafi, M.; Lee, L.-Y. Actinometric and Φ -order photodegradation of anti-cancer Sunitinib. *J. Pharm. Biomed. Anal.* **2015**, 110, 34-41.
19. Maafi, M.; Al-Qarni, M.A.; Φ -order spectrophotokinetic characterisation and quantification of trans-cis oxyresveratrol reactivity, photodegradation and actinometry. *Spectrochimica Acta Part A: Mol. Biomol. Spectr.* **2018**, 188, 64-71.
20. Maafi, M.; Maafi, W. Modelling and elucidation of the kinetics of multiple consecutive photoreactions AB₄(4 Φ) with Φ -order kinetics. Application to the photodegradation of riboflavin. *J. Pharm. Sci.* **2016**, 105, 3537-3548.
21. Bonifazi, E.; Angeini, G.; Meneghini, C.L. Adverse photo-reaction of dacarbazine (DTIC). *Contact Dermatitis.* **1981**, 7, 161.

22. Sutow, W.W.; Maurer, H.M. Chemotherapy of sarcomas- a perspective. *Semin. Oncol.* **1981**, 8, 207–214.
23. Eichenauer, D.A.; Engert, A. Advances in the treatment of Hodgkin lymphoma. *Int. J. Hematol.* **2012**, 96, 535–543.
24. Jiang, G.; Li, R.H.; Sun, C.; Liu, Y.Q.; Zheng, J.N. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis. *PLoS ONE.* **2014**, 9, e111920.
25. Raimundo Gonçalves de Oliveira Júnior, R.; Bonnet, Braconnier, E.; Groult, H.; Prunier, G.; Beaugeard, L.; Grougnet, R.; Guedes da Silva, J.R.; Alves Ferraz, C.A.;
26. Picot, L. Bixin, an apocarotenoid isolated from *Bixa orellana* L., sensitizes human melanoma cells to dacarbazine-induced apoptosis through ROS-mediated cytotoxicity. *Food and Chem. Toxicol.* **2019**, 125, 549-561.
27. Steffens, I.; Morás, A.M.; Arantes, P.R.; Masterson, K.; Cao, Z.; Nugent, M.; Moura, D.J. Electrospun PVA-dacarbazine nanofibers as a novel nano brain-implant for treatment of glioblastoma: in silico and in vitro characterization. *Eur. J. Pharm. Sci.* **2020**, 143, 105183.
28. Kawabe, K.; Nakamura, H.; Hino, E.; Suzuki, S. Photochemical stabilities of some dihydropyridine calcium-channel blockers in powdered pharmaceutical tablets. *J. Pharm. Biomed. Anal.* **2008**, 47, 618-624.
29. Toal, C.B.; Meredith, P.A.; Elliott, H.L. Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: A literature review comparing amlodipine and nifedipine GITS. *Blood Pressure.* **2012**, 21, 3-10
30. Zulfeen, M.; Tatapudi, R.; Sowjanya, R. IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy—A randomized controlled trial. *Eur. J. Obst. Gynec. Reprod. Biol.* **2019**, 236, 46-52.

31. Yao, J.; Long, H.; Zhao, J.; Zhong, G.; Li, J. Nifedipine inhibits oxidative stress and ameliorates osteoarthritis by activating the nuclear factor erythroid-2-related factor 2 pathway. *Life Sci.* **2020**, 117292.
32. Majeed, I.A.; Murray, W.J.; Newton, D.W.; Othman, S.; Al-Turk, W.A. Spectrophotometric study of the photodecomposition kinetics of nifedipine. *J. Pharm. Pharmacol.* **1987**, 39, 1044-1046. 1987
33. Shamsipur, M.; Hemmateenejad, B.; Akhond, M.; Javidnia, K.; Miri, R. A study of the photodegradation kinetics of nifedipine by multivariate curve resolution analysis. *J. Pharm. Biomed. Anal.* **2003**, 31, 1013-1019.
34. Mattos, C.B.; Deponti, V.B.; Barreto, F.; Simoes, C.M.O.; Andrighetti-Frohner, C.R.; Nunes, R.J.; Steindel, M.; Teixeira, H.F.; Koester, L.S. development of a stability-indicating LC method for the determination of a synthetic chalcone derivatives in a nanoemulsion dosage form and identification of the main photodegradation product by LC-MS. *J. Pharm. Biomed. Anal.* **2012**, 70, 652-656.
35. Sangoi, M.S.; Todeschini, V.; Goelzer, G.K.; Steppe, M. Photochemistry of a novel antimuscarinic drug fesoterodine and identification of its photodegradation products by LC-ESI-MS studies. *J. Photochem. Photobiol. A Chem.* **2013**, 256, 16-22.
36. De Luca, M.; Ioele, G.; Ragno, G. 1,4-Dihydropyridine Antihypertensive Drugs: Recent Advances in Photostabilization Strategies. *Pharmaceutics*. **2019**, 11, 85.
37. Douglas Mc G. Clarkson, D.M.; Harvey, R.; Sheepy, D. Light protection of chemotherapy drugs for infusion. *Med. Eng. Phys.* **2015**, 37, 233-238.
38. Uchida, A.; Ohtake, H.; Suzuki, Y.; Satoh, H.; Setoh, Y.; Onoue, S.; Oguchi, T. Photochemically stabilized formulation of dacarbazine with reduced production of allogenic photodegradants. *Int. J. Pharm.* **2019**, 564, 492–498493.
39. Maafi, M.; Maafi, W. Quantification of unimolecular photoreaction kinetics: determination of quantum yields and development of actinometers – the photodegradation case of cardiovascular drug Nisoldipine. *Int. J. Photoenergy*. **2015**, 1.

- 880 40. Maafi, M.; Maafi, W. Quantitative assessment of photostability and photostabilisation
881 of fluvoxamine and its design for actinometry. *Photochem. Photobiol. Sci.* **2015**, 14,
882 982-994.
- 883 41. Baertschi, S.W. Commentary on the quinine actinometry system described in the ICH
884 draft guideline on photostability testing of new drug substances and products. *Drug*
885 *Stabil.* **1997**, 1, 193-195.
- 886 42. Baertschi, S.W.; Alsante, K.M.; Tonnesen, H.H. A critical assessment of the ICH
887 guideline on photostability testing of new drug substances and products (Q1B):
888 recommendation for revision. *J. Pharm. Sci.* **2010**, 99, 2934-2940.
- 889 43. Allain, L.R.; Baertschi, S.W.; Clapham, D.; Foti, C.; Lantaff, W.M.; Reed,
890 R.A.; Templeton, A.C.; Tønnesen, H.H. Implications of In-Use Photostability:
891 Proposed Guidance for Photostability Testing and Labeling to Support the
892 Administration of Photosensitive Pharmaceutical Products, Part 3. Oral Drug Products.
893 *J. Pharm. Sci.* **2016**, 105, 1586-1594.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [GA.png](#)